The goal of cancer immunotherapy is to elicit a robust immune response to search, recognize, engage, and eradicate cancer cells. In a normal, healthy person our immune cells, in particular, T cells, play a vital role in recognizing tumors and removing them.

Despite the approval of immunotherapies such as Keytruda (anti-PD-1), Opdivo (anti-PD-1), Yervoy (anti-CTLA-4) and Tecentriq (anti-PD-L1), there are a number of factors that lead to therapy resistance in patients. However, thanks to breakthroughs in cancer research coupled with technological advancements, several factors have been identified that impede the ability of immune cells to effectively recognize and kill tumors.  These factors include:

  • Evading recognition by T cells

  • Influencing T cell trafficking and infiltration

  • Affecting T cell metabolism

  • Dysregulation the function of T cells

  • Resisting killing by T cells

  • Inducing apoptosis of T cells

So where do we go from here?

Our Objectives

  • Streamline the traditional services model

  • Be creative in how we offer our services

  • Cost-effective to cater to all our partner’s needs (from start-up to  big pharma)